NAPLEX 2026 — Oncology Practice Exam 1

Thirty-nine single-best-answer items with five options, eight select-all-that-apply items and three numeric fill-in items. Cancer biology and screening; cell-cycle-specific and non-specific cytotoxics with the toxicities that define them, including vinca neurotoxicity, anthracycline cardiotoxicity, platinum nephrotoxicity and neuropathy, bleomycin pulmonary fibrosis, ifosfamide neurotoxicity and haemorrhagic cystitis; fluoropyrimidine and methotrexate safety with rescue and antidote strategies; taxane and nab-paclitaxel administration; extravasation of vesicants; targeted and hormonal therapy including HER2, EGFR, VEGF and BCR-ABL agents; immune checkpoint inhibitors and immune-mediated toxicity; supportive care across CINV, febrile neutropenia, growth factors, anaemia, mucositis and diarrhoea; oncologic emergencies including tumour lysis syndrome and hypercalcaemia of malignancy; hazardous-drug handling; and the oncology calculations behind absolute neutrophil count, body-surface-area dosing, Calvert carboplatin dosing and infusion rates.